New imaging agent lets doctors watch Cancer-Fighting cells in action

NCT ID NCT07280793

Not yet recruiting Knowledge-focused Sponsor: Xuzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a new PET imaging agent called 68Ga-NOTA-BCMA to see if it can safely and accurately show where anti-BCMA CAR-T cells go in the body and how long they last. Ten adults with multiple myeloma who are scheduled for CAR-T therapy will receive the tracer and undergo PET/CT scans. The goal is to gather information on the tracer's distribution and safety, not to treat the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BCMA-TARGETED PET IMAGING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BCMA-TARGETED PET IMAGING CAR-T CELL BIODISTRIBUTION AND PERSISTENCE GMP-COMPLIANT RADIOPHARMACEUTICAL PREPARATION NON-INVASIVE CAR-T CELL MONITORING

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.